BPC-157 Capsules vs Injectable — What Does Research Say?
BPC-157 (Body Protection Compound-157) has been extensively studied as a systemic peptide, but its oral form has a distinct and arguably more intuitive application: gastrointestinal healing. The peptide is a 15-amino acid sequence derived from gastric juice protein, and early research by Sikirić et al. (University of Zagreb) demonstrated potent gastroprotective effects even when delivered orally.
Oral Bioavailability Research
Conventional wisdom held that peptides are degraded in the GI tract and cannot exert systemic effects orally. BPC-157 challenges this assumption:
- Rat models of IBD, gastric ulcer, and colitis showed equivalent healing outcomes between oral and subcutaneous BPC-157 administration in several Zagreb laboratory studies
- The proposed mechanism: BPC-157 acts locally on intestinal epithelium and enteric nervous system before being absorbed, providing direct mucosal effects that do not require systemic bioavailability
- Upregulation of growth factors (EGF, VEGF) in intestinal tissue has been demonstrated following oral dosing
Key Research Applications
- Inflammatory bowel disease (IBD): Significant reduction in inflammatory markers and mucosal damage scores in TNBS-induced colitis models
- Gastric ulcer protection: Faster ulcer healing and gastroprotection against NSAID-induced damage
- Gut-brain axis: Emerging research suggests BPC-157 modulates the vagus nerve and serotonin pathways from the gut, with anxiolytic implications
- Leaky gut: Preclinical evidence of tight junction restoration in intestinal permeability models
Research Notes
For researchers studying systemic effects (muscle, tendon, CNS), injectable BPC-157 remains the established protocol. For gastrointestinal-focused research, oral capsules provide a targeted, convenient, and well-tolerated route.
See also: BPC-157 Injectable Research for full systemic mechanism data.